DexCom, Inc.
(DXCM)
DexCom's Asymmetric Setup: A Base Case Funded by Existing Demand, Biggest Catalyst a Free Option
The central tension in Dexcom is whether its non-insulin type 2 expansion is a margin-accretive growth wave or a commoditization trap. The resolution is in the sequencing. The catalysts that drive the next several quarters — commercial coverage of all diabetics this summer, G7...
Read Article ›